Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

The incidence of serious adverse events did not differ significantly between combo therapy and monotherapy in patients with immune-mediated inflammatory diseases. However, specific combinations such ...

Patients with rheumatoid arthritis (RA) whose symptoms improved after they started taking nonbiologic disease-modifying antirheumatic drugs (DMARDs) also demonstrated restored balance in their oral ...

About one-third of patients prefer in-hospital administration, particularly if they are older or already make frequent visits to the hospital. Most patients with rheumatoid arthritis (RA) would prefer ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

Still's disease is an unusual form of arthritis that, in children, is also called systemic juvenile idiopathic arthritis, but it can also develop in adults. Few rigorous studies have examined biologic ...

Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes ...

Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of this pathway would be a novel ...

How long do you need to take a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis before it's fully effective? It depends on which one you use. But they all take a while, says Eric ...